CURIS INC (CRIS) Stock Price, Quote, News and Overview
NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD
CRIS Quote, Performance and Key Statistics
2.3
-0.14 (-5.74%)
The current stock price of CRIS is 2.3 USD. In the past month the price decreased by -6.12%. In the past year, price decreased by -73.98%.
CRIS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.23 | 330.76B | ||
| AMGN | AMGEN INC | 13.95 | 155.70B | ||
| GILD | GILEAD SCIENCES INC | 14.13 | 136.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.01 | 52.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.61B | ||
| ARGX | ARGENX SE - ADR | 100.28 | 35.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.80B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.44 | 27.21B | ||
| NTRA | NATERA INC | N/A | 21.87B | ||
| BIIB | BIOGEN INC | 8.33 | 19.32B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.31B |
Related stock screener links
About CRIS
Company Profile
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Company Info
CURIS INC
128 Spring Street, Building C, Suite 500
Lexington MASSACHUSETTS 02421 US
CEO: James Dentzer
Employees: 34
Phone: 16175036500
CURIS INC / CRIS FAQ
What is the stock price of CURIS INC today?
The current stock price of CRIS is 2.3 USD. The price decreased by -5.74% in the last trading session.
What is the ticker symbol for CURIS INC stock?
The exchange symbol of CURIS INC is CRIS and it is listed on the Nasdaq exchange.
On which exchange is CRIS stock listed?
CRIS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CURIS INC stock?
10 analysts have analysed CRIS and the average price target is 16.32 USD. This implies a price increase of 609.57% is expected in the next year compared to the current price of 2.3. Check the CURIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CURIS INC worth?
CURIS INC (CRIS) has a market capitalization of 24.06M USD. This makes CRIS a Nano Cap stock.
How many employees does CURIS INC have?
CURIS INC (CRIS) currently has 34 employees.
What are the support and resistance levels for CURIS INC (CRIS) stock?
CURIS INC (CRIS) has a support level at 2.12 and a resistance level at 2.47. Check the full technical report for a detailed analysis of CRIS support and resistance levels.
Is CURIS INC (CRIS) expected to grow?
The Revenue of CURIS INC (CRIS) is expected to grow by 13.24% in the next year. Check the estimates tab for more information on the CRIS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CURIS INC (CRIS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRIS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRIS, evaluating the profitability, health, valuation and growth aspects
- CURIS INC (CRIS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CURIS INC (CRIS) Sales and EPS estimates to see what analysts future expectations are.
- CURIS INC (CRIS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CURIS INC (CRIS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CURIS INC (CRIS) Stock Chart to make your own analysis
- CURIS INC (CRIS) Latest news and press-releases to stay up to date.
Does CURIS INC (CRIS) stock pay dividends?
CRIS does not pay a dividend.
When does CURIS INC (CRIS) report earnings?
CURIS INC (CRIS) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of CURIS INC (CRIS)?
CURIS INC (CRIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.23).
What is the Short Interest ratio of CURIS INC (CRIS) stock?
The outstanding short interest for CURIS INC (CRIS) is 1.06% of its float. Check the ownership tab for more information on the CRIS short interest.
CRIS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CRIS. When comparing the yearly performance of all stocks, CRIS is a bad performer in the overall market: 95.13% of all stocks are doing better.
CRIS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRIS. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative.
CRIS Financial Highlights
Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -6.23. The EPS increased by 27.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CRIS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to CRIS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 55.36% and a revenue growth 13.24% for CRIS